Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the initiation of a Phase 1b clinical trial for its self-developed new drug, XH-S004, designed for the treatment of chronic obstructive pulmonary disease (COPD) in China, excluding the Hong Kong SAR, Macau SAR, and Taiwan region. Developed by S-INFINITY Co., Ltd., a subsidiary of Fosun Pharma, XH-S004 is a small molecule oral DPP-1 inhibitor. It targets neutrophils by inhibiting DPP-1 and neutrophil-activated serine proteases, aiming to reduce chronic inflammatory responses and associated airway damage in COPD. The drug seeks to address a significant unmet need in COPD treatment, as current therapies have limited efficacy in preventing acute exacerbations or slowing disease progression. Additionally, XH-S004 is undergoing a Phase II clinical trial for the treatment of non-cystic fibrosis bronchiectasis in Mainland China. No results from the current trial have been presented yet.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。